Forskolin, with its unique ability to elevate intracellular cAMP levels, sets off a signaling cascade by activating adenylyl cyclase, thereby potentially enhancing the protein kinase A (PKA) pathway and indirectly upregulating C17orf78 activity if it is responsive to cAMP. The compound IBMX complements this process by preserving the integrity of cAMP and cGMP pools, indirectly sustaining the signaling milieu that could bolster C17orf78 activity. The dynamic interplay of calcium ions within the cell is another fulcrum of regulation, with Ionomycin acting to increase intracellular calcium concentration, thus impacting pathways that might govern C17orf78 activity if it is sensitive to calcium-mediated signaling. Similarly, PMA recruits protein kinase C (PKC) into action, which could serve to modulate C17orf78 if PKC signaling influences its regulatory network.
Tyrosine phosphorylation is yet another layer of cellular control, with Sodium orthovanadate acting to inhibit protein tyrosine phosphatases, thereby potentially enhancing tyrosine kinase signaling that might touch upon C17orf78's sphere of regulation. Lithium chloride, by inhibiting GSK-3β, could shift the balance in Wnt/β-catenin signaling, a pathway that, if intertwined with C17orf78, would be subject to modulation. Targeting the phosphoinositide 3-kinase (PI3K) with LY294002, or mTOR with Rapamycin, exemplifies a strategy to influence the network of growth and metabolism-related signaling, which, if connected to C17orf78, could result in altered activity levels of this protein. The phosphatase inhibitor Okadaic acid operates by maintaining phosphorylation states that could reverberate through to C17orf78, while KN-93 and PD98059, which inhibit CaMKII and MEK respectively, along with SB203580 acting on p38 MAPK, represent chemical interventions aimed at modulating kinase signaling pathways that could have a downstream effect on the activity of C17orf78.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Inhibits cAMP and cGMP phosphodiesterases, maintaining signaling through these messengers which could support the activity of C17orf78 if it is downstream of these. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates protein kinase C (PKC), which could modulate signaling pathways that influence C17orf78 activity if PKC is part of its regulatory network. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases intracellular calcium levels, potentially affecting C17orf78 if it is regulated by calcium-dependent signaling mechanisms. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $45.00 $56.00 $183.00 | 142 | |
Inhibits protein tyrosine phosphatases, which can enhance tyrosine kinase signaling, potentially influencing C17orf78 activity if it is tyrosine phosphorylation-dependent. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3β and may impact Wnt/β-catenin signaling, which could affect C17orf78 activity if it interacts with this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially impacting AKT signaling and possibly C17orf78 activity if it is within the PI3K/AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which could modulate signaling pathways that regulate C17orf78 if it is involved in cell growth and metabolism control. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Inhibits serine/threonine phosphatases like PP1 and PP2A, potentially altering phosphorylation states that could influence C17orf78 activity. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
Inhibits CaMKII; if C17orf78 is modulated by calcium/calmodulin-dependent processes, this could affect its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, potentially affecting the MAPK/ERK pathway, which could modulate C17orf78 activity if it is downstream of this pathway. |